Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective boosted by JPMorgan Chase & Co. from $272.00 to $280.00 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the stock. Scotiabank cut their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Piper Sandler restated an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Royal Bank of Canada restated an “outperform” rating and issued a $310.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Trading Down 0.3 %

ALNY stock opened at $241.75 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a market capitalization of $31.30 billion, a price-to-earnings ratio of -111.41 and a beta of 0.39. The firm’s fifty day simple moving average is $254.86 and its two-hundred day simple moving average is $260.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $41,529,000. Truist Financial Corp raised its holdings in shares of Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock worth $1,035,000 after acquiring an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after acquiring an additional 8,462 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after acquiring an additional 2,285 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.